Block Listing Review and Total Voting Rights

RNS Number : 5452X

ReNeuron Group plc

01 September 2020

 

 

1 September 2020

AIM: RENE

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

Name:	ReNeuron Group plc
Name of Scheme:	ReNeuron Share Option Schemes
Period of Return:	From 1 March 2020 to 31 August 2020
Balance of unallotted securities under scheme(s) from previous return:	715,241 Ordinary Shares (of 1p each)
Plus : The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for):	N/A
Less : Number of securities issued/allotted under scheme(s) during period	40,554
Equals : Balance under scheme(s) not yet issued/allotted at end of period:	674,687 Ordinary Shares
Number and class of securities originally admitted and the date of admission:	20,000 ordinary shares on 13 May 2010

Total Voting Rights

At 31 August 2020, the Company had 31,874,324 Ordinary Shares in issue, all with voting rights. This follows the issue of 26,120 new shares arising from the exercise of options by staff, such shares having been admitted under the above block listing arrangement.

As the Company holds no ordinary shares in treasury, the figure of 31,874,324 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

ENDS

ENQUIRIES:

ReNeuron	[phone]
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (Media/Investor relations)	[phone]
Mark Court, Tilly Abraham
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace	[phone]
N+1 Singer (Joint Broker) Aubrey Powell, James Moat, Tom Salvesen	[phone]

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. 

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com .

 

END

 

 

MSCKKDBBFBKDKFN